35 completed. 35 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 35 | Completed 35 |
| Phase 2 | 3 | Completed 3 |
Follow Metaplasia: new trials by email Literature Review of Metaplasia trials Research Report on Metaplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy Brolucizumab 6mg - Macular Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | Completed | Novartis Pharmaceuticals | 148 | 2023-02-06 | 2025-12-15 |
| A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration RTH258/Brolucizumab - Neovascular Age Related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 210 | 2021-01-26 | 2024-10-09 |
| An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study brolucizumab - Neovascular Age-related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 248 | 2020-12-16 | 2024-10-09 |
| Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration RTH258/Brolucizumab - Neovascular Age-Related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 295 | 2020-12-14 | 2024-11-07 |
| Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy Brolucizumab 6 mg, Panretinal photocoagulation laser - Proliferative Diabetic Retinopathy | Phase 3 | Completed | Novartis Pharmaceuticals | 689 | 2020-11-19 | 2025-10-16 |
| Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) Brolucizumab 6 mg, Aflibercept 2 mg - Age-related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 734 | 2019-09-25 | 2024-10-09 |
| Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution - Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization | Phase 3 | Completed | Alcon Research | 1048 | 2015-07-28 | 2025-01-16 |
| Efficacy and Safety of RTH258 Versus Aflibercept - Study 1 Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution - Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization | Phase 3 | Completed | Alcon Research | 1775 | 2014-12-08 | 2025-01-16 |
| A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. Ranibizumab - Choroidal Neovascularization Secondary to Pathologic Myopia | Phase 3 | Completed | Novartis Pharmaceuticals | 200 | 2014-06-10 | 2019-02-18 |
| Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD Ranibizumab 0.5mg - Age-related Macular Degeneration, Choroidal Neovascularization | Phase 3 | Completed | Novartis Pharmaceuticals | 650 | 2013-12-17 | 2017-04-17 |
| An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. ranibizumab - Choroidal Neovascularization, Macular Edema | Phase 3 | Completed | Novartis Pharmaceuticals | 270 | 2013-09-26 | 2019-08-12 |
| Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Ranibizumab 0.5mg, Ranibizumab 0.5 mg, Verteporfin PDT - Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM) | Phase 3 | Completed | Novartis Pharmaceuticals | 457 | 2013-09-11 | 2019-06-24 |
| Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization. Ranibizumab, Sham control - Choroidal Neovascularization (CNV) | Phase 3 | Completed | Novartis Pharmaceuticals | 183 | 2013-09-01 | 2016-08-26 |
| Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia Bevazizumab intravitreal injection - Choroidal Subfoveal/Juxtafoveal Neovascularization in High Myopia | Phase 3 | Completed | Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA | 66 | 2012-10-01 | 2023-03-13 |
| A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD Recombinant Human VEGF Receptor-Fc Fusion Protein - Neovascular Age-related Macular Degeneration | Phase 3 | Completed | Chengdu Kanghong Biotech Co., Ltd. | 125 | 2011-08-01 | 2023-04-18 |
| VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) VEGF Trap-Eye (BAY86-5321), No Drug - Myopia, Pathological | Phase 3 | Completed | Bayer | 122 | 2010-12-01 | 2014-05-05 |
| Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Ranibizumab, Verteporfin PDT, Sham Ranibizumab - Pathological Myopia | Phase 3 | Completed | Novartis Pharmaceuticals | 277 | 2010-10-01 | 2014-02-10 |
| Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia Intravitreal Injection, Photodynamic Therapy (Visudyne) - Myopia, Choroidal Neovascularization | Phase 3 | Completed | Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA | 56 | 2008-04-01 | 2024-10-31 |
| Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial ranibizumab, bevacizumab - Age Related Macular Degeneration | Phase 3 | Completed | University of Pennsylvania | 1208 | 2008-02-01 | 2017-08-21 |
| EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) ranibizumab - Choroidal Neovascularization, Age-Related Macular Degeneration | Phase 3 | Completed | Novartis | 95 | 2007-06-01 | 2016-11-18 |
Showing 20 of 35. Sign in to see all of them.
Choroidal Neovascularization (29) · Macular Degeneration (19) · Vision Disorders (5) · Eye Diseases (3) · Geographic Atrophy (3) · Myopia, Degenerative (3) · Retinal Diseases (3) · Retinal Neovascularization (3) · Wet Macular Degeneration (3) · Diabetic Retinopathy (2) · Neovascularization, Pathologic (2) · Angioid Streaks (1) · Corneal Neovascularization (1) · Diabetes Mellitus (1) · Disease (1)
Pathologic Processes (35) · Pathological Conditions, Signs and Symptoms (35) · Neovascularization, Pathologic (33) · Eye Diseases (32) · Choroid Diseases (30) · Uveal Diseases (30) · Retinal Diseases (23) · Retinal Degeneration (19) · Nervous System Diseases (6) · Neurologic Manifestations (6) · Sensation Disorders (6) · Signs and Symptoms (6) · Cardiovascular Diseases (5) · Refractive Errors (4)
Ranibizumab (12) · brolucizumab (8) · Bevacizumab (5) · Verteporfin (5) · aflibercept (4) · Photochemotherapy (3) · Triamcinolone Acetonide (2) · 1-phenyl-3,3-dimethyltriazene (1) · Intravitreal Injections (1) · Triamcinolone (1) · pegaptanib (1)
Novartis Pharmaceuticals (13) · National Eye Institute (NEI) (3) · Novartis (3) · Alcon Research (2) · Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA (2) · Medical University of Vienna (2) · Asociación para Evitar la Ceguera en México (1) · Bayer (1) · Chengdu Kanghong Biotech Co., Ltd. (1) · Eyetech Pharmaceuticals (1) · Genentech, Inc. (1) · Johns Hopkins University (1) · Shahid Beheshti University of Medical Sciences (1) · University Hospital, Basel, Switzerland (1) · University of Pennsylvania (1)
South Korea (10) · United States (10) · France (7) · Spain (7) · Switzerland (7) · Italy (6) · Canada (5) · Germany (5) · Portugal (5) · Taiwan (5) · Australia (4) · India (4) · Turkey (Türkiye) (4) · Austria (3) · Belgium (3)
Daniel F Martin, MD (1) · David J Wilson, MD (1) · Douglas A Jabs, MD, MBA (1) · Glenn Jaffe,, MD (1) · Hamid Ahmadieh, MD (1) · Jose Maria Ruiz-Moreno, MD PhD (1) · Juan E Grunwald, MD (1) · Maureen G Maguire, PhD (1) · Neil M Bressler, MD (1)
PMID 30986442, PMID 32374423, PMID 33207259, PMID 34968756, PMID 37343623, PMID 39033924, PMID 17659962, PMID 19643495, PMID 21526923, PMID 22150050, PMID 22382503, PMID 22444829, PMID 22452699, PMID 22512984, PMID 22555112, PMID 22939114, PMID 23047002, PMID 23337555, PMID 23642377, PMID 23706946, PMID 24084496, PMID 24314839, PMID 24326106, PMID 24652518, PMID 24727261, PMID 24835760, PMID 24875610, PMID 24949820, PMID 25064723, PMID 25109929, PMID 25220133, PMID 25307130, PMID 25542520, PMID 25600198, PMID 25824327, PMID 26028346, PMID 26102433, PMID 26143666, PMID 26383996, PMID 26545320, PMID 26681392, PMID 26778329, PMID 26783095, PMID 27040149, PMID 27099955, PMID 28079023, PMID 28974567, PMID 29454660, PMID 30189282, PMID 30476517
2019 (3), 2014 (1), U10EY017823 (1)